HRTX (STOCKS)
Heron Therapeutics, Inc.
$0.409800
+0.009700 (+2.42%)
Prev close: $0.400100
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Craig A. Collard
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $75.90M
- Employees
- 122
- P/E (TTM)
- -2.29
- P/B (TTM)
- 9.33
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
6
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.04 | $-0.02 | -0.0247 | -161.44% |
|
Dec 2025 (Q4)
|
$-0.02 | $-0.02 | +0.0004 | +1.96% |
|
Sep 2025 (Q3)
|
$-0.04 | $-0.02 | -0.0247 | -161.44% |
|
Jun 2025 (Q2)
|
$-0.02 | $-0.01 | -0.0098 | -96.08% |
Financial Statements
| Revenues | $150.71M |
| Benefits Costs and Expenses | $145.74M |
| Cost Of Revenue | $43.53M |
| Costs And Expenses | $117.64M |
| Gross Profit | $107.18M |
| Operating Expenses | $117.64M |
| Research and Development | $12.54M |
| Other Operating Expenses | $105.11M |
| Operating Income/Loss | -$10.46M |
| Income/Loss From Continuing Operations After Tax | -$30.94M |
| Income/Loss From Continuing Operations Before Tax | -$5.63M |
| Net Income/Loss | -$30.94M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$30.94M |
| Net Income/Loss Available To Common Stockholders, Basic | -$30.94M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.17 |
| Diluted Earnings Per Share | -$0.17 |
| Basic Average Shares | 521,197,000 |
| Diluted Average Shares | 521,197,000 |
| Assets | $246.22M |
| Current Assets | $228.98M |
| Cash | $44.80M |
| Inventory | $92.54M |
| Other Current Assets | $91.65M |
| Noncurrent Assets | $17.23M |
| Fixed Assets | $12.03M |
| Other Non-current Assets | $5.21M |
| Liabilities | $237.08M |
| Current Liabilities | $90.52M |
| Accounts Payable | $8.97M |
| Wages | $6.39M |
| Other Current Liabilities | $75.16M |
| Noncurrent Liabilities | $146.56M |
| Equity | $9.14M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $9.14M |
| Liabilities And Equity | $246.22M |
| Net Cash Flow From Operating Activities | -$20.26M |
| Net Cash Flow From Operating Activities, Continuing | -$20.26M |
| Net Cash Flow From Investing Activities | $12.80M |
| Net Cash Flow From Investing Activities, Continuing | $12.80M |
| Net Cash Flow From Financing Activities | $14.31M |
| Net Cash Flow From Financing Activities, Continuing | $14.31M |
| Net Cash Flow | $6.85M |
| Net Cash Flow, Continuing | $6.85M |
| Comprehensive Income/Loss | -$30.95M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$30.95M |
| Other Comprehensive Income/Loss | -$19.88M |